Sort
10,766 grants matching “checkpoint inhibitor”
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma
$352,275Sherie L Morrison · University Of California Los Angeles · R01 · FY2017 · CA
Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and Immunity
$352,275Taslim A Al-Hilal · Utah State Higher Education System--University Of Utah · R01 · FY2025 · CA
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma
$352,275Sherie L Morrison · University Of California Los Angeles · R01 · FY2018 · CA
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
$352,275Fekadu Kassie · University Of Minnesota · R01 · FY2020 · CA
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
$352,275Fekadu Kassie · University Of Minnesota · R01 · FY2021 · CA
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma
$352,275Sherie L Morrison · University Of California Los Angeles · R01 · FY2016 · CA
Anti-CD138-IFN fusion proteins for the immunotherapy of multiple myeloma
$352,275Sherie L Morrison · University Of California Los Angeles · R01 · FY2020 · CA
Dual function of HSP70 in cytoprotection of tumor cells and generation of permissive microenvironment
$352,275Hasan Korkaya · Augusta University · R01 · FY2021 · CA
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
$352,275Fekadu Kassie · University Of Minnesota · R01 · FY2019 · CA
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
$352,275Ahmed Chadli · Augusta University · R01 · FY2021 · CA
Role of an unusual GTPase in DNA damage response and carcinogenesis
$352,219Sam W Lee · Massachusetts General Hospital · R01 · FY2009 · CA
Role of an unusual GTPase in DNA damage response and carcinogenesis
$352,219Sam W Lee · Massachusetts General Hospital · R01 · FY2010 · CA
Role of an unusual GTPase in DNA damage response and carcinogenesis
$352,219Sam W Lee · Massachusetts General Hospital · R01 · FY2008 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer
$352,120Benjamin G Bitler · University Of Colorado Denver · R37 · FY2022 · CA
Optimizing systemic immunotherapy for personalized brain metastasis treatment
$352,061Michael Lim · Stanford University · U54 · FY2021 · CA
Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis
$352,047Florencia McAllister · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$352,047Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Harnessing Aurora kinase inhibitionâinduced cell death to enhance immunotherapy in HPVâdriven cancers
$352,047Faye Johnson · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$352,047Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$352,047Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
$352,047Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$352,047Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
$352,032Robert M Prins · University Of California Los Angeles · P50 · FY2017 · CA
Targeted therapies in cutaneous melanoma
$351,975Andrew E Aplin · Thomas Jefferson University · R01 · FY2024 · CA
The Role of Stromal Autophagy in Cutaneous Melanoma
$351,964Hilary A Coller · University Of California Los Angeles · R01 · FY2022 · CA